1. Cardiovascular & Metabolic Diseases, MedImmune, Cambridge, United Kingdom;
2. Drug Safety and Metabolism, AstraZeneca, Gothenburg, Sweden;
3. Cardiovascular & Metabolic Diseases, AstraZeneca, Gothenburg, Sweden;
4. Sahlgrenska University, Gothenburg, Sweden;
5. Institute for Biomedical Research Alberto Sols, CSIC, UAM, Madrid, Spain;
6. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM, ISCIII), Madrid, Spain; and
7. Drug Safety and Metabolism, AstraZeneca, Cheshire, United Kingdom